Psychiatric Stigmatization

R. Persaud

DOI: https://doi.org/10.1177/014107689809100128

1998-01-01

Journal of the Royal Society of Medicine

Abstract:

What problem does this paper attempt to address?

Using co‐design methods to develop new personalised support for people living with Long Covid: The 'LISTEN' intervention

Fiona Jones,Anne Domeny,Jessica Fish,Fiona Leggat,Ian Patel,Jackie McRae,Carol Rowe,Monica E. Busse

DOI: https://doi.org/10.1111/hex.14093

2024-05-26

Health Expectations

Abstract:Introduction Many Covid‐19 survivors are living with unresolved, relapsing and remitting symptoms and no 'one size' of treatment is likely to be effective for everyone. Supported self‐management for the varied symptoms of Long Covid (LC) is recommended by the National Institute for Health and Care Excellence in the United Kingdom. We aimed to develop a new personalised support intervention for people living with LC using a structured co‐design framework to guide replication and evaluation. Methods We used the improvement methodology, Experience‐Based Co‐Design, in an accelerated form to harness the collective experiences of people with LC. Incorporating evidence from 'Bridges Self‐Management' (Bridges) an approach in which healthcare professionals (HCPs)are trained to support knowledge, confidence and skills of individuals living with long term conditions. Co‐designed resources are also central to Bridges. Adults who self‐identified as living with or recovered from LC, from England or Wales, aged 18 years and over were recruited, and HCPs, with experience of supporting people with LC. Participants took part in a series of small co‐design group meetings and larger mixed meetings to agree priorities, core principles and generate resources and intervention content. Results People with LC (n = 28), and HCPs (n = 9) supported co‐design of a book (hard‐copy and digital form) to be used in 1:1 support sessions with a trained HCP. Co‐design stages prioritised stories about physical symptoms first, and psychological and social challenges which followed, nonlinear journeys and reconceptualising stability as progress, rich descriptions of strategies and links to reputable advice and support for navigating healthcare services. Co‐design enabled formulation of eight core intervention principles which underpinned the training and language used by HCPs and fidelity assessments. Conclusion We have developed a new personalised support intervention, with core principles to be used in one‐to‐one sessions delivered by trained HCPs, with a new co‐designed book as a prompt to build personalised strategies and plans using narratives, ideas, and solutions from other people with LC. Effectiveness and cost effectiveness of the 'LISTEN' intervention will be evaluated in a randomised controlled trial set within the context of the updated Framework for Developing and Evaluating Complex Interventions. Patient and Public Contribution The LISTEN Public and Patient Involvement (PPI) group comprised seven people living with LC. They all contributed to the design of this study and five members were part of a larger co‐design community described in this paper. They have contributed to this paper by interpreting stages of intervention design and analysis of results. Three members of our PPI group are co‐authors of this paper.

public, environmental & occupational health,health care sciences & services,health policy & services
Online multimodal rehabilitation programme to improve symptoms and quality of life for adults diagnosed with long COVID-19: a Randomised Clinical Trial protocol

Sandra León-Herrera,Rosa Magallón-Botaya,Bárbara Oliván-Blázquez,Lucía Sagarra-Romero,Carlos Martín Jaurrieta,Fátima Méndez-López

DOI: https://doi.org/10.3389/fpubh.2023.1222888

IF: 5.2

2023-09-08

Frontiers in Public Health

Abstract:Background: Long COVID is a multisystemic condition which affects quality of life and implies a multidisciplinary treatment approach. There is still limited evidence on management techniques for this syndrome. "Telerehabilitation" could be an important tool when addressing the symptoms of this patients with the aim of increasing their quality of life. The purpose of this trial is to analyse the effectiveness of an online multimodal rehabilitation programme to improve the symptomatology of people with long COVID and their quality of life. Methods: A pragmatic randomised controlled trial will be performed with two parallel groups: (1) usual treatment by the primary care practitioner (Treatment as usual, TAU; control group) and (2) TAU plus the use of an online multimodal rehabilitation programme, including videoconferences and content published on a Moodle platform (intervention group). The data will be collected before and after the intervention. A follow-up will take place 3 months later. Discussion: There is still a lack of knowledge regarding the management of the symptoms of long COVID. This creates the need to add scientific evidence about the care of this disease, considering that multidisciplinary social and health teams can offer the necessary care so that these patients can recover their previous quality of life. Clinical trial registration : The protocol for this study was registered with the ISRCTN Registry [registration number: ISRCTN15414370] on 28 December 2022.

public, environmental & occupational health
Personalised Health Behaviour Support Programme in Adults With Post‐COVID Syndrome: A Randomised, Controlled Pilot Feasibility Trial

Matthew Armstrong,Rebecca Owen,Kristen Shirley Van Niekerk,Zoe L. Saynor

DOI: https://doi.org/10.1111/hex.70079

2024-10-28

Health Expectations

Abstract:Background We investigated whether a novel 8‐week personalised health behaviour support programme, focusing on the stability of symptoms and strategies to improve activities of daily living, was feasible and acceptable in adults with post‐COVID syndrome. Methods In this randomised, controlled, pilot feasibility trial, 32 adults with post‐COVID syndrome (continued symptoms for ≥ 12 weeks) were randomised 1:1 to receive personalised health behaviour support (self‐reported physical activity and symptom diaries, plus seven one‐to‐one remotely delivered personalised self‐management support sessions), once weekly for 8‐weeks, or usual care (referral to online 'your COVID‐19 recovery' programme). The primary outcome was the feasibility of recruiting and randomising adults with post‐COVID syndrome. The secondary outcomes were to assess the acceptability and safety of the intervention and various outcome measures. Results Of the 48 adults who expressed interest in the study, 32 (67%) were eligible and completed the baseline assessment. All 32 adults were willing to be randomised to either the personalised health behaviour support programme (n = 17) or usual care (n = 15) and 27 (age: 45 ± 12 years) adults completed follow‐up at 9 weeks. The intervention was deemed feasible, with high adherence (92% and 94% completion rates for the physical activity and symptom diaries, respectively) and excellent acceptability rates (94% 'liked the intervention a lot'). The intervention was deemed safe, with no symptom exacerbations reported. Conclusion An 8‐week personalised health behaviour support programme was feasible for adults with post‐COVID syndrome, with good adherence and acceptability rates. Early pilot data from this small sample also suggests meaningful improvements in physical activity, fatigue and respiratory symptoms. Patient or Public Contribution People living with post‐COVID syndrome were involved from the outset with the study design, review of study documentation and interpretation of the data following completion. Furthermore, several participants have supported the local dissemination of findings following the completion of the study.

public, environmental & occupational health,health care sciences & services,health policy & services
A trial of dextromethorphan in parkinsonian patients with motor response complications

L. Metman,P. Blanchet,P. van den Munckhof,P. Dotto,R. Natté,T. Chase

DOI: https://doi.org/10.1002/mds.870130307

IF: 9.698

1998-05-01

Movement Disorders

Abstract:The effects of the NMDA antagonist dextromethorphan (DM) on levodopa‐associated dyskinesias and motor fluctuations were studied in patients with advanced Parkinson's disease. During initial open‐label dose escalation, 6 of 18 patients reported a beneficial effect at their individually determined optimal DM dose (range, 60–120 mg/day). The 12 remaining patients either experinced reversible side effects, particularly mild drowsiness, or decreased levodopa efficacy, and were therefore excluded from the study. The six responders entered the double‐blind, placebo‐controlled, crossover study with two 2‐week arms separted by 1 week wash‐out. On the last day of each arm, motor ratings were performed every 20 minutes for 8 consecutive hours. In addition, motor complications and Activities of Daily Living (ADL) were assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) and patient diaries. With DM, dyskinesias improved by 25% according to physician's ratings and by 40% accfording to UPDRS interviews, without compromising the anti‐Parkinson effect of levodopa. Motor fluctuations and ADL scores also improved significantly. Although the narrow therapeutic index of DM limits its clinical usefulness, these findings support the view that drugs acting to inhibit glutamatergic transmission at the NMDA receptor can ameliorate levodopa‐associated motor complications.
Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines.

David M. Brown,M. Wilson,W. Macnee,V. Stone,K. Donaldson

DOI: https://doi.org/10.1006/TAAP.2001.9240

IF: 4.46

2001-09-15

Toxicology and Applied Pharmacology

Abstract:Studies into the effects of ultrafine particles in the lung have shown adverse effects considered to be due in part to the particle size. Air pollution particles (PM(10)) are associated with exacerbations of respiratory disease and deaths from cardiovascular causes in epidemiological studies and the ultrafine fraction of PM(10) has been hypothesized to play an important role. The aim of the present study was to investigate proinflammatory responses to various sizes of polystyrene particles as a simple model of particles of varying size including ultrafine. In the animal model, we demonstrated that there was a significantly greater neutrophil influx into the rat lung after instillation of 64-nm polystyrene particles compared with 202- and 535-nm particles and this was mirrored in other parameters of lung inflammation, such as increased protein and lactate dehydrogenase in bronchoalveolar lavage. When surface area instilled was plotted against inflammation, these two variables were directly proportional and the line passed through zero. This suggests that surface area drives inflammation in the short term and that ultrafine particles cause a greater inflammatory response because of the greater surface area they possess. In vitro, we measured the changes in intracellular calcium concentration in mono mac 6 cells in view of the potential role of calcium as a signaling molecule. Calcium changes after particle exposure may be important in leading to proinflammatory gene expression such as chemokines. We demonstrated that only ultrafine polystyrene particles induced a significant increase in cytosolic calcium ion concentration. Experiments using dichlorofluorescin diacetate demonstrated greater oxidant activity of the ultrafine particles, which may explain their activity in these assays. There were significant increases in IL-8 gene expression in A549 epithelial cells after treatment with the ultrafine particles but not particles of other sizes. These findings suggest that ultrafine particles composed of low-toxicity material such as polystyrene have proinflammatory activity as a consequence of their large surface area. This supports a role for such particles in the adverse health effects of PM(10).
Biosound Therapy as a treatment for long COVID patients: A pre-post pilot study

Colleenia Korapatti,Lauren Vera,Keith Miller

DOI: https://doi.org/10.1016/j.explore.2024.04.004

Abstract:Background: 43 % of people who are diagnosed with COVID-19 will experience persistent symptoms, also known as "long COVID," which lasts past the recovery of the acute infection. Long COVID symptoms overlap with symptoms that the Biosound Therapy System (BTS) has been shown to improve. The BTS is a multimodal treatment that includes biofeedback, vibroacoustic therapy synchronized with music that plays binaural beats, and video content. This study aimed to determine feasibility for a future full-scale Randomized Controlled Trial (RCT) and explore the impact of the BTS on long COVID symptoms. Methods: This pre-post pilot study was conducted in an outpatient mental health clinic. Adults aged 20-65 years old with persistent COVID-19 symptoms were screened and randomly assigned to the intervention or control group. The intervention group was given 8 Biosound Therapy sessions during a period of 4 weeks. All participants were assessed at baseline and at post-intervention using the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-item scale (GAD-7), Cambridge Brain Sciences (CBS) tasks, and the COVID-19 Persistent Symptom Questionnaire. The feasibility outcomes were recruitment rates, retention rates, and open-ended questions about participants' experiences. Results: 15 participants enrolled in the study and 13 completed the study (9 intervention, 4 control). Trial recruitment ended prematurely due to the emergence of the Omicron variant of COVID-19. Participants responded to open-ended questions with only positive remarks and made no comments on the study not being feasible. A Wilcoxon signed-rank test indicated that compared to baseline, participants in the intervention group had significant improvement in their GAD-7 score, PHQ9 score, 2 Cambridge Brain Science tasks ("Odd" and "Double Trouble"), fatigue, and difficulties in concentrating or remembering (p < 0.05; 95 % CI). Conclusion: The intervention group showed promising improvement without reported side effects. A full-scale RCT is feasible as long as the recruitment setting is changed to a location that allows access to more patients with long COVID. Results were limited due to the small sample size; therefore, a full-scale trial is needed.
Self-managing symptoms of Long COVID: an education and strategies research protocol

Julia Rybkina,Nithin Jacob,Brenda Colella,David Gold,Donna E. Stewart,Lesley A. Ruttan,Liesel-Ann C. Meusel,Mary P. McAndrews,Susan Abbey,Robin Green

DOI: https://doi.org/10.3389/fpubh.2024.1106578

IF: 5.2

2024-02-08

Frontiers in Public Health

Abstract:Post-acute sequelae of SARS-COV-2 (PASC) is growing in prevalence, and involves symptoms originating from the central neurological, cardiovascular, respiratory, gastrointestinal, autonomic nervous, or immune systems. There are non-specific symptoms such as fatigue, headaches, and brain fog, which cannot be ascribed to a single system. PASC places a notable strain on our healthcare system, which is already laden with a large number of acute-COVID-19 patients. Furthermore, it impedes social, academic and vocational functioning, and impacts family life, relationships, and work/financial life. The treatment for PASC needs to target this non-specific etiology and wide-ranging sequelae. In conditions similar to PASC, such as "chemo brain," and prolonged symptoms of concussion, the non-specific symptoms have shown to be effectively managed through education and strategies for self-management and Mindfulness interventions. However, such interventions have yet to be empirically evaluated in PASC to our knowledge. In response to this gap, we have developed a virtual education intervention synthesized by psychiatrists and clinical psychologists for the current study. We will undertake a two-phase randomized controlled trial to determine the feasibility (Phase 1; N = 90) and efficacy (Phase 2; sample sized based on phase 1 results) of the novel 8 week Education and Self-Management Strategies group compared to a mindfulness skills program, both delivered virtually. Main outcomes include confidence/ability to self-manage symptoms, quality of life, and healthcare utilization. This study stands to mitigate the deleterious intrusiveness of symptoms on everyday life in patients with PASC, and may also help to reduce the impact of PASC on the healthcare system. Clinical trial registration: https://classic.clinicaltrials.gov/ct2/show/NCT05268523; identifier NCT05268523.

public, environmental & occupational health
An exploration of the experiences and self-generated strategies used when navigating everyday life with Long Covid

Fiona J. Leggat,Celayne Heaton-Shrestha,Jessica Fish,Aloysius Niroshan Siriwardena,Anne Domeney,Carol Rowe,Ian Patel,Judith Parsons,John Blair,Fiona Jones

DOI: https://doi.org/10.1186/s12889-024-18267-6

IF: 4.5

2024-03-13

BMC Public Health

Abstract:Abstract Background Around one in ten people who contract Covid-19 report ongoing symptoms or ‘Long Covid’. Without any known interventions to cure the condition, forms of self-management are routinely prescribed by healthcare professionals and described by people with the condition. However, there is limited research exploring what strategies are used to navigate everyday life with Long Covid, and experiences that initiate development of these strategies. Our study aimed to explore the range and influence of self-generated strategies used by people with Long Covid to navigate everyday life within the context of their own condition. Methods Forming part of the Long Covid Personalised Self-managemenT support co-design and EvaluatioN (LISTEN) project, we conducted a qualitative study using narrative interviews with adults who were not hospitalised with Covid-19. Participants aged over 18 years, who self-identified with Long Covid, were recruited from England and Wales. Data were analysed with patient contributors using a reflexive thematic analysis. Results Eighteen participants (mean age = 44 years, SD = 13 years) took part in interviews held between December 2021 and February 2022. Themes were constructed which depicted 1) the landscape behind the Long Covid experience and 2) the everyday experience of participants’ Long Covid. The everyday experience comprised a combination of physical, emotional, and social factors, forming three sub-themes: centrality of physical symptoms, navigating ‘experts’ and the ‘true colour’ of personal communities, and a rollercoaster of psychological ambiguity ). The third theme, personal strategies to manage everyday life was constructed from participants’ unique presentations and self-generated solutions to manage everyday life. This comprised five sub-themes: seeking reassurance and knowledge, developing greater self-awareness through monitoring, trial and error of ‘safe’ ideas, building in pleasure and comfort, and prioritising ‘me’ . Conclusions Among this sample of adults with Long Covid, their experiences highlighted the unpredictable nature of the condition but also the use of creative and wide ranging self-generated strategies. The results offer people with Long Covid, and healthcare professionals supporting them, an overview of the collective evidence relating to individuals' self-management which can enable ways to live ‘better’ and regain some sense of identity whilst facing the impact of a debilitating, episodic condition. Trial registration LISTEN ISRCTN36407216.

public, environmental & occupational health
Robotics in special needs education

M. Virnes

DOI: https://doi.org/10.1145/1463689.1463710

2008-06-11

Abstract:The purpose of this study is to explore the potential of robotics as an educational tool in special needs education. Qualitative case studies are used to increase knowledge about programmable LEGO NXT and Topobo robotics constructions kits in special needs education, and about the social robot and Topobo that are used in early childhood education when possible learning disabilities have not yet been diagnosed. This study aims to provide suggestions about how robotics might be used to recognize disabilities at an early stage of education and to compensate for them in learning.
Estimation of fault-free leakage current using wafer-level spatial information

S. Sabade,D. Walker

DOI: https://doi.org/10.1109/TVLSI.2005.863183

IEEE Transactions on Very Large Scale Integration (VLSI) Systems

Abstract:Leakage current or the I/sub DDQ/ test has been shown to be an effective test screen in combination with traditional test methods. However, leakage current is rising rapidly as semiconductor technology advances. This makes it difficult to distinguish between faulty and fault-free chips using traditional threshold setting methods. This paper presents a method to estimate leakage current using neighboring chip information on a wafer. Outlier chips are rejected, and a least-squares-fit plane through neighboring chips is used to estimate defect-free I/sub DDQ/. Chips that significantly deviate from the estimate are rejected. The proposed method is evaluated using industrial test data.
An Artificial Intelligence-Driven Digital Health Solution to Support Clinical Management of Patients With Long COVID-19: Protocol for a Prospective Multicenter Observational Study

Aïna Fuster-Casanovas,Luis Fernandez-Luque,Francisco J Nuñez-Benjumea,Alberto Moreno Conde,Luis G Luque-Romero,Ioannis Bilionis,Cristina Rubio Escudero,Irene Alice Chicchi Giglioli,Josep Vidal-Alaball

DOI: https://doi.org/10.2196/37704

2022-10-14

Abstract:Background: COVID-19 pandemic has revealed the weaknesses of most health systems around the world, collapsing them and depleting their available health care resources. Fortunately, the development and enforcement of specific public health policies, such as vaccination, mask wearing, and social distancing, among others, has reduced the prevalence and complications associated with COVID-19 in its acute phase. However, the aftermath of the global pandemic has called for an efficient approach to manage patients with long COVID-19. This is a great opportunity to leverage on innovative digital health solutions to provide exhausted health care systems with the most cost-effective and efficient tools available to support the clinical management of this population. In this context, the SENSING-AI project is focused on the research toward the implementation of an artificial intelligence-driven digital health solution that supports both the adaptive self-management of people living with long COVID-19 and the health care staff in charge of the management and follow-up of this population. Objective: The objective of this protocol is the prospective collection of psychometric and biometric data from 10 patients for training algorithms and prediction models to complement the SENSING-AI cohort. Methods: Publicly available health and lifestyle data registries will be consulted and complemented with a retrospective cohort of anonymized data collected from clinical information of patients diagnosed with long COVID-19. Furthermore, a prospective patient-generated data set will be captured using wearable devices and validated patient-reported outcomes questionnaires to complement the retrospective cohort. Finally, the 'Findability, Accessibility, Interoperability, and Reuse' guiding principles for scientific data management and stewardship will be applied to the resulting data set to encourage the continuous process of discovery, evaluation, and reuse of information for the research community at large. Results: The SENSING-AI cohort is expected to be completed during 2022. It is expected that sufficient data will be obtained to generate artificial intelligence models based on behavior change and mental well-being techniques to improve patients' self-management, while providing useful and timely clinical decision support services to health care professionals based on risk stratification models and early detection of exacerbations. Conclusions: SENSING-AI focuses on obtaining high-quality data of patients with long COVID-19 during their daily life. Supporting these patients is of paramount importance in the current pandemic situation, including supporting their health care professionals in a cost-effective and efficient management of long COVID-19. Trial registration: Clinicaltrials.gov NCT05204615; https://clinicaltrials.gov/ct2/show/NCT05204615. International registered report identifier (irrid): DERR1-10.2196/37704.
Low-temperature structure of Ba0.6K0.4BiO3.

Kwei,Goldstone,Lawson,Thompson,Williams

DOI: https://doi.org/10.1103/PHYSREVB.39.7378

1989-04-01

Abstract:The newly discovered copper-free superconductor Ba/sub 1-//sub x/K/sub x/BiO/sub 3/ has the CaTiO/sub 3/-type structure at room temperature, but its structure at or below T/sub c/ is not known. We report Rietveld refinements of the structures fit to neutron-powder-diffraction data taken at 297 and 10 K for a sample with x = 0.4. We find that the structure remains cubic at 10 K, the dopant level remains close to that expected from the starting stoichiometry, the oxygen sites are essentially fully occupied, and the anisotropic thermal ellipsoids remain oblate with the unique axis along the Bi-O-Bi bonds.
Impairment of Pupillary Responses and Optokinetic Nystagmus in the mGluR6-deficient Mouse

H. Iwakabe,G. Katsuura,C. Ishibashi,S. Nakanishi

DOI: https://doi.org/10.1016/S0028-3908(96)00167-0

IF: 5.273

1997-02-01

Neuropharmacology

Abstract:
Impact of long COVID on health-related quality-of-life: an OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT)

Oliver Carlile,Andrew Briggs,Alasdair D Henderson,Ben F C Butler-Cole,John Tazare,Laurie A Tomlinson,Michael Marks,Mark Jit,Liang-Yu Lin,Chris Bates,John Parry,Sebastian C J Bacon,Iain Dillingham,William A Dennison,Ruth E Costello,Alex J Walker,William Hulme,Ben Goldacre,Amir Mehrkar,Brian MacKenna,OpenSAFELY Collaborative,Emily Herrett,Rosalind M Eggo,Alex Walker,Amelia Green,Andrea Schaffer,Andrew Brown,Ben Butler-Cole,Caroline Morton,Caroline Walters,Catherine Stables,Christine Cunningham,Christopher Wood,Colm Andrews,David Evans,George Hickman,Helen Curtis,Henry Drysdale,Jessica Morley,Jon Massey,Linda Nab,Lisa Hopcroft,Louis Fisher,Lucy Bridges,Milan Wiedemann,Nicholas DeVito,Orla Macdonald,Peter Inglesby,Rebecca Smith,Richard Croker,Robin Park,Rose Higgins,Sebastian Bacon,Simon Davy,Steven Maude,Thomas O'Dwyer,Tom Ward,Victoria Speed,Liam Hart,Pete Stokes,Krishnan Bhaskaran,Ruth Costello,Thomas Cowling,Ian Douglas,Rosalind Eggo,Stephen Evans,Harriet Forbes,Richard Grieve,Daniel Grint,Sinead Langan,Viyaasan Mahalingasivam,Kathryn Mansfield,Rohini Mathur,Helen McDonald,Edward Parker,Christopher Rentsch,Anna Schultze,Liam Smeeth,Laurie Tomlinson,Jemma Walker,Elizabeth Williamson,Kevin Wing,Angel Wong,Bang Zheng,Christopher Bates,Jonathan Cockburn,Frank Hester,Sam Harper,Shaun O'Hanlon,Alex Eavis,Richard Jarvis,Dima Avramov,Paul Griffiths,Aaron Fowles,Nasreen Parkes,Rafael Perera,David Harrison,Kamlesh Khunti,Jonathan Sterne,Jennifer Quint

DOI: https://doi.org/10.1016/j.lanepe.2024.100908

2024-04-24

Abstract:Background: Long COVID is a major problem affecting patient health, the health service, and the workforce. To optimise the design of future interventions against COVID-19, and to better plan and allocate health resources, it is critical to quantify the health and economic burden of this novel condition. We aimed to evaluate and estimate the differences in health impacts of long COVID across sociodemographic categories and quantify this in Quality-Adjusted Life-Years (QALYs), widely used measures across health systems. Methods: With the approval of NHS England, we utilised OpenPROMPT, a UK cohort study measuring the impact of long COVID on health-related quality-of-life (HRQoL). OpenPROMPT invited responses to Patient Reported Outcome Measures (PROMs) using a smartphone application and recruited between November 2022 and October 2023. We used the validated EuroQol EQ-5D questionnaire with the UK Value Set to develop disutility scores (1-utility) for respondents with and without Long COVID using linear mixed models, and we calculated subsequent Quality-Adjusted Life-Months (QALMs) for long COVID. Findings: The total OpenPROMPT cohort consisted of 7575 individuals who consented to data collection, with which we used data from 6070 participants who completed a baseline research questionnaire where 24.6% self-reported long COVID. In multivariable regressions, long COVID had a consistent impact on HRQoL, showing a higher likelihood or odds of reporting loss in quality-of-life (Odds Ratio (OR): 4.7, 95% CI: 3.72-5.93) compared with people who did not report long COVID. Reporting a disability was the largest predictor of losses of HRQoL (OR: 17.7, 95% CI: 10.37-30.33) across survey responses. Self-reported long COVID was associated with an 0.37 QALM loss. Interpretation: We found substantial impacts on quality-of-life due to long COVID, representing a major burden on patients and the health service. We highlight the need for continued support and research for long COVID, as HRQoL scores compared unfavourably to patients with conditions such as multiple sclerosis, heart failure, and renal disease. Funding: This research was supported by the National Institute for Health and Care Research (NIHR) (OpenPROMPT: COV-LT2-0073).
Addressing psychosocial needs in patients with Long-COVID (PsyLoCo-Study): study protocol of a pilot-study of a specialized modular intervention

Christine Allwang,Tamara Frank,Paul Bruckmann,Andreas Dinkel,Marius Binneboese,Hannah Wallis,Melanie Elgner,Katrin E. Giel,Marisa Schurr,Harald Gündel,Lisa Wedekind,Julia Kuhn,Claas Lahmann,Anne-Maria Müller,Pauline Beckmann,Janka Massag,Rafael Mikolajczyk,Florian Junne

DOI: https://doi.org/10.3389/fpsyt.2024.1305691

IF: 4.7

2024-03-07

Frontiers in Psychiatry

Abstract:Introduction: After an acute infection with the corona virus 10-20% of those affected suffer from ongoing or new symptoms. A causal therapy for the phenomenon known as Long/Post-COVID is still lacking and specific therapies addressing psychosocial needs of these patients are imperatively needed. The aim of the PsyLoCo-study is developing and piloting a psychotherapeutic manual, which addresses Long/Post-COVID-related psychosocial needs and supports in coping with persistent bodily symptoms as well as depressive or anxiety symptoms. Methods and analysis: This pilot trial implements a multi-centre, 2-arm (N=120; allocation ratio: 1:1), parallel group, randomised controlled design. The pilot trial is designed to test the feasibility and estimate the effect of 1) a 12-session psychotherapeutic intervention compared to 2) a wait-list control condition on psychosocial needs as well as bodily and affective symptoms in patients suffering from Long/Post-COVID. The intervention uses an integrative, manualized, psychotherapeutic approach. The primary study outcome is health-related quality of life. Outcome variables will be assessed at three timepoints, pre-intervention (t1), post-intervention (t2) and three months after completed intervention (t3). To determine the primary outcome, changes from t1 to t2 are examined. The analysis will be used for the planning of the RCT to test the efficacy of the developed intervention. Discussion: The pilot study will evaluate a 12-session treatment manual for Long/Post-COVID sufferers and the therapy components it contains. The analysis will provide insights into the extent to which psychotherapeutic treatment approaches improve the symptoms of Long/Post-COVID sufferers. The treatment manual is designed to be carried out by psychotherapists as well as people with basic training in psychotherapeutic techniques. This approach was chosen to enable a larger number of practitioners to provide therapeutic support for Long/Post-COVID patients. After completion of the pilot study, it is planned to follow up with a randomized controlled study and to develop a treatment guideline for general practitioners and interested specialists. Trial registration: The pilot trial has been registered with the German Clinical Trials Register (Deutsches Register Klinischer Studien; Trial-ID: DRKS00030866; URL: https://drks.de/search/de/trial/DRKS00030866) on March 7, 2023.

psychiatry
LOng COvid Multidisciplinary consortium Optimising Treatments and servIces acrOss the NHS (LOCOMOTION): protocol for a mixed-methods study in the UK

Sivan,M.,Greenhalgh,T.,Darbyshire,J. L.,Mir,G.,O'Connor,R. J.,Dawes,H.,Greenwood,D.,OConnor,D.,Horton,M.,Petrou,S.,de Lusignan,S.,Curcin,V.,Mayer,E.,Casson,A.,Milne,R.,Rayner,C.,Smith,N.,Parkin,A.,Preston,N.,Delaney,B.,on behalf of the LOCOMOTION consortium,Bakerly,Barahona,Casson,Clarke,Curcin,Davies,Dawes,Delaney,Echevarria,Elkin,Evans,Falope,Ben Glampson,Halpin,Horton,Kwon,Lusignan,Delanerolle,Mayer,Master,Milne,Morris,Parkin,Pick,Preston,Rebane,Tucker,Espinosa Gonzalez,Baley,Rolls,Bullock,Ball,Bashir,Mansoubi,Elwin,Prociuk,Qureshi,Jones

DOI: https://doi.org/10.1136/bmjopen-2022-063505

IF: 3.006

2022-05-18

BMJ Open

Abstract:Introduction Long COVID, a new condition whose origins and natural history are not yet fully established, currently affects 1.5 million people in the UK. Most do not have access to specialist long COVID services. We seek to optimise long COVID care both within and outside specialist clinics, including improving access, reducing inequalities, helping self-management and providing guidance and decision support for primary care. We aim to establish a 'gold standard' of care by systematically analysing current practices, iteratively improving pathways and systems of care. Methods and analysis This mixed-methods, multisite study is informed by the principles of applied health services research, quality improvement, co-design, outcome measurement and learning health systems. It was developed in close partnership with patients (whose stated priorities are prompt clinical assessment; evidence-based advice and treatment and help with returning to work and other roles) and with front-line clinicians. Workstreams and tasks to optimise assessment, treatment and monitoring are based in three contrasting settings: workstream 1 (qualitative research, up to 100 participants), specialist management in 10 long COVID clinics across the UK, via a quality improvement collaborative, experience-based co-design and targeted efforts to reduce inequalities of access, return to work and peer support; workstream 2 (quantitative research, up to 5000 participants), patient self-management at home, technology-supported monitoring and validation of condition-specific outcome measures and workstream 3 (quantitative research, up to 5000 participants), generalist management in primary care, harnessing electronic record data to study population phenotypes and develop evidence-based decision support, referral pathways and analysis of costs. Study governance includes an active patient advisory group. Ethics and dissemination LOng COvid Multidisciplinary consortium Optimising Treatments and servIces acrOss the NHS study is sponsored by the University of Leeds and approved by Yorkshire & The Humber—Bradford Leeds Research Ethics Committee (ref: 21/YH/0276). Participants will provide informed consent. Dissemination plans include academic and lay publications, and partnerships with national and regional policymakers. Trial registration number NCT05057260, ISRCTN15022307.

medicine, general & internal
Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial

Christine Norton,Jonathan Syred,Sally Kerry,Micol Artom,Louise Sweeney,Ailsa Hart,Wladyslawa Czuber-Dochan,Stephanie J C Taylor,Borislava Mihaylova,Chris Roukas,Qasim Aziz,Laura Miller,Richard Pollok,Sonia Saxena,Imogen Stagg,Helen Terry,Zohra Zenasni,Lesley Dibley,Rona Moss-Morris

DOI: https://doi.org/10.1186/s13063-021-05466-4

IF: 2.728

2021-08-03

Trials

Abstract:Background: Despite being in clinical remission, many people with inflammatory bowel disease (IBD) live with fatigue, chronic abdominal pain and bowel urgency or incontinence that limit their quality of life. We aim to test the effectiveness of an online self-management programme (BOOST), developed using cognitive behavioural principles and a theoretically informed logic model, and delivered with facilitator support. Primary research question: In people with IBD who report symptoms of fatigue, pain or urgency and express a desire for intervention, does a facilitator-supported tailored (to patient needs) online self-management programme for fatigue, pain and faecal urgency/incontinence improve IBD-related quality of life (measured using the UK-IBDQ) and global rating of symptom relief (0-10 scale) compared with care as usual? Methods: A pragmatic two-arm, parallel group randomised controlled trial (RCT), of a 12-session facilitator-supported online cognitive behavioural self-management programme versus care as usual to manage symptoms of fatigue, pain and faecal urgency/incontinence in IBD. Patients will be recruited through a previous large-scale survey of unselected people with inflammatory bowel disease. The UK Inflammatory Bowel Disease Questionnaire and global rating of symptom relief at 6 months are the co-primary outcomes, with multiple secondary outcomes measured also at 6 and 12 months post randomisation to assess maintenance. The RCT has an embedded pilot study, health economics evaluation and process evaluation. We will randomise 680 patients, 340 in each group. Demographic characteristics and outcome measures will be presented for both study groups at baseline. The UK-IBDQ and global rating of symptom relief at 6 and 12 months post randomisation will be compared between the study groups. Discussion: The BOOST online self-management programme for people with IBD-related symptoms of fatigue, pain and urgency has been designed to be easily scalable and implemented. If it is shown to improve patients' quality of life, this trial will enable clinicians and patients to make informed management decisions. This is the first trial, to our knowledge, focused on multiple symptoms prioritised by both people with IBD and health professionals. Trial registration: ISRCTN71618461 . Registered on 9 September 2019.
Diphenylhydantoin: Effects on Calcium Metabolism in the Chick

M. Villareale,L. V. Gould,R. Wasserman,A. Barr,R. T. Chiroff,W. H. Bergstrom

DOI: https://doi.org/10.1126/science.183.4125.671

IF: 56.9

1974-02-15

Science

Abstract:Rickets, hypocalcemia, decreased duodenal calcium transport, and reduction of calcium binding protein have been produced in chicks treated with diphenylhydantoin. These effects are directly related to diphenylhydantoin dose and inversely related to the intake of vitamin D3 (cholecalciferol).
Protocol for a pilot study: Feasibility of a web-based platform to improve nutrition, mindfulness, and physical function in people living with Post COVID-19 condition (BLEND)

Montserrat Montes-Ibarra,Kristine Godziuk,Richard B Thompson,Catherine B Chan,Edith Pituskin,Douglas P Gross,Grace Lam,Mathias Schlögl,João Felipe Mota,D Ian Paterson,Carla M Prado

DOI: https://doi.org/10.1016/j.ymeth.2024.10.004

IF: 4.647

Methods

Abstract:Individuals with Post COVID-19 condition (PCC), or long COVID, experience symptoms such as fatigue, muscle weakness, and psychological distress, including anxiety, depression, or sleep disorders that persist after recovery from COVID-19. These ongoing symptoms significantly compromise quality of life and diminish functional capacity and independence. Multimodal digital interventions targeting behavioural factors such as nutrition and mindfulness have shown promise in improving health outcomes of people with chronic health conditions and may be beneficial for those with PCC. The BLEND study (weB-based pLatform to improve nutrition, mindfulnEss, and physical function, in patients with loNg COVID) study is an 8-week pilot randomized controlled trial evaluating the feasibility of a digital wellness platform compared to usual care among individuals with PCC. The web-based wellness platform employed in this study, My Viva Plan (MVP)®, integrates a holistic, multicomponent approach to promote wellness. The intervention group receives access to the digital health platform for 8 weeks with encouragement for frequent interactions to improve dietary intake and mindfulness. The control group receives general content focusing on improvements in dietary intake and mindfulness. Assessments are conducted at baseline and week 8. The primary outcome is the feasibility of platform use. Secondary and exploratory outcomes include a between-group comparison of changes in body composition, nutritional status, quality of life, mindfulness, physical activity, and physical performance after 8 weeks. Findings of this study will inform the development of effective web-based wellness programs tailored for individuals with PCC to promote sustainable behavioural changes and improved health outcomes.
ITM support for patients with chronic respiratory and cardiovascular diseases: a protocol for a randomised controlled trial

Julie Redfern,Karice Hyun,Anna Singleton,Nashid Hafiz,Rebecca Raeside,Lissa Spencer,Bridie Carr,Ian Caterson,John Cullen,Cate Ferry,Karla Santo,Alison Hayes,Regina W M Leung,Simon Raadsma,Jessica Swinbourne,Jin G Cho,Meredith King,Mary Roberts,Cindy Kok,Christine Jenkins,Clara Chow

DOI: https://doi.org/10.1136/bmjopen-2018-023863

IF: 3.006

2019-03-01

BMJ Open

Abstract:Introduction: Simple and scalable strategies are needed to improve 'out-of-hospital' support and management for people living with cardiovascular disease (CVD) and respiratory disease. Text messaging via mobile phones has been shown to be effective in helping promote lifestyle change and is supported by quantitative and qualitative evidence. The aim of this study is to test the effectiveness and implementation of a 6-month text messaging support programme for people with CVD and respiratory disease as an addition to cardiac and pulmonary outpatient rehabilitation. Methods and analysis: Pragmatic randomised controlled trial (n=310) to test the effectiveness of a 6-month text message support programme on clinical outcomes in people with CVD and chronic respiratory disease who are attending outpatient cardiac and pulmonary rehabilitation. The study includes a nested process evaluation to inform scalability and implementation across settings. The intervention group will receive a text message support programme comprising five messages per week for 26 weeks and the control group will continue with standard care. The primary outcome is exercise capacity (6 min walk distance). Secondary outcomes include clinical measures (proportion of people meeting the Australian guideline-recommended blood pressure and cholesterol targets), lifestyle outcomes (smoking rates, achievement of national guidelines for nutrition and physical activity), quality of life, mood (Hospital Anxiety and Depression Scale), medication adherence and attendance at and completion of rehabilitation. Ethics and dissemination: Primary ethics approval was received from the Sydney Local Health District Hospital Human Research Ethics Committee and associated Governance committees at sites. Results will be disseminated via the usual scientific forums including peer-reviewed publications and presentations at international conferences. At its conclusion, the study will determine the effectiveness and implementation of a simple programme that aims to improve health outcomes and attendance at rehabilitation for people with CVD and chronic respiratory disease. Trial registration number: ACTRN12616001167459.

Psychiatric Stigmatization

Using co‐design methods to develop new personalised support for people living with Long Covid: The 'LISTEN' intervention

Online multimodal rehabilitation programme to improve symptoms and quality of life for adults diagnosed with long COVID-19: a Randomised Clinical Trial protocol

Personalised Health Behaviour Support Programme in Adults With Post‐COVID Syndrome: A Randomised, Controlled Pilot Feasibility Trial

A trial of dextromethorphan in parkinsonian patients with motor response complications

Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines.

Biosound Therapy as a treatment for long COVID patients: A pre-post pilot study

Self-managing symptoms of Long COVID: an education and strategies research protocol

An exploration of the experiences and self-generated strategies used when navigating everyday life with Long Covid

Robotics in special needs education

Estimation of fault-free leakage current using wafer-level spatial information

An Artificial Intelligence-Driven Digital Health Solution to Support Clinical Management of Patients With Long COVID-19: Protocol for a Prospective Multicenter Observational Study

Low-temperature structure of Ba0.6K0.4BiO3.

Impairment of Pupillary Responses and Optokinetic Nystagmus in the mGluR6-deficient Mouse

Impact of long COVID on health-related quality-of-life: an OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT)

Addressing psychosocial needs in patients with Long-COVID (PsyLoCo-Study): study protocol of a pilot-study of a specialized modular intervention

LOng COvid Multidisciplinary consortium Optimising Treatments and servIces acrOss the NHS (LOCOMOTION): protocol for a mixed-methods study in the UK

Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial

Diphenylhydantoin: Effects on Calcium Metabolism in the Chick

Protocol for a pilot study: Feasibility of a web-based platform to improve nutrition, mindfulness, and physical function in people living with Post COVID-19 condition (BLEND)

ITM support for patients with chronic respiratory and cardiovascular diseases: a protocol for a randomised controlled trial